Our HTDS assays identified several combinations of EGFR+MTOR/AKT pathway inhibitors as effective at inhibiting the growth of EGFR-driven GBM samples, with erlotinib+MLN0128 ranking first (Figure 1e). The gene discussed is AKT1; the disease is glioblastoma.